HBM Holdings Receives FDA IND Clearance for HBM7004 Bispecific Antibody Targeting Advanced Solid Tumors

Bulletin Express05-08

HBM Holdings Limited announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for HBM7004, allowing the company to launch a first-in-human Phase I clinical trial in the United States.

The upcoming Phase I study will evaluate safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of HBM7004 in patients with advanced solid tumors.

HBM7004 is a novel B7H4xCD3 bispecific antibody generated via the company’s proprietary HBICE platform. Preclinical studies demonstrated tumor-specific, B7H4-dependent T-cell activation, robust anti-tumor efficacy, high in-vivo stability and reduced systemic toxicity. In addition, preclinical data indicated a strong synergistic effect when HBM7004 was combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, suggesting an encouraging therapeutic window.

The company cautioned that successful development and commercialization of HBM7004 are not guaranteed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195129725?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195129725","market":"hk","top_or_hot":-1,"title":"HBM Holdings Receives FDA IND Clearance for HBM7004 Bispecific Antibody Targeting Advanced Solid Tumors","media":"Bulletin Express","content":"<p>HBM Holdings Limited announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for HBM7004, allowing the company to launch a first-in-human Phase I clinical trial in the United States.</p>\n<p>The upcoming Phase I study will evaluate safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of HBM7004 in patients with advanced solid tumors.</p>\n<p>HBM7004 is a novel B7H4xCD3 bispecific antibody generated via the company’s proprietary HBICE platform. Preclinical studies demonstrated tumor-specific, B7H4-dependent T-cell activation, robust anti-tumor efficacy, high in-vivo stability and reduced systemic toxicity. In addition, preclinical data indicated a strong synergistic effect when HBM7004 was combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, suggesting an encouraging therapeutic window.</p>\n<p>The company cautioned that successful development and commercialization of HBM7004 are not guaranteed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Receives FDA IND Clearance for HBM7004 Bispecific Antibody Targeting Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Receives FDA IND Clearance for HBM7004 Bispecific Antibody Targeting Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-08 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HBM Holdings Limited announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for HBM7004, allowing the company to launch a first-in-human Phase I clinical trial in the United States.</p>\n<p>The upcoming Phase I study will evaluate safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of HBM7004 in patients with advanced solid tumors.</p>\n<p>HBM7004 is a novel B7H4xCD3 bispecific antibody generated via the company’s proprietary HBICE platform. Preclinical studies demonstrated tumor-specific, B7H4-dependent T-cell activation, robust anti-tumor efficacy, high in-vivo stability and reduced systemic toxicity. In addition, preclinical data indicated a strong synergistic effect when HBM7004 was combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, suggesting an encouraging therapeutic window.</p>\n<p>The company cautioned that successful development and commercialization of HBM7004 are not guaranteed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1195129725","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195129725","pubTimestamp":1778231007,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HBM Holdings Limited announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for HBM7004, allowing the company to launch a first-in-human Phase I...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"HBM Holdings靶向晚期实体瘤的HBM7004双特异性抗体获得FDA IND许可","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"HBM Holdings Limited announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for HBM7004, allowing the company to launch a first-in-human Phase I clinical trial in the United States.\nThe upcoming Phase I study will evaluate safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of HBM7004 in patients with advanced solid tumors.\nHBM7004 is a novel B7H4xCD3 bispecific antibody generated via the company’s proprietary HBICE platform. Preclinical studies demonstrated tumor-specific, B7H4-dependent T-cell activation, robust anti-tumor efficacy, high in-vivo stability and reduced systemic toxicity. In addition, preclinical data indicated a strong synergistic effect when HBM7004 was combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, suggesting an encouraging therapeutic window.\nThe company cautioned that successful development and commercialization of HBM7004 are not guaranteed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195129725","isCrawlerRequest":true}